Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine with Imagery Rescripting for Subclinical PTSD
NCT03216356Phase 3Withdrawn
- Start
- Sep 2016
- Primary completion
- Dec 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of d-cycloserine in post-traumatic stress disorder (PTSD). Planned start Sep 2016; status: withdrawn.
02
Drugs
d-cycloserine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03216356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216356.